Fig. 4

Effects of cisplatin exposure on sncRNA epimutations. A Boxplot of 22G-RNA epimutations rate for each generation of the MA lines compared to the pre-mutation generation F0 and for each condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). No significant difference was observed between conditions (Kruskal–Wallis rank-sum test, p-value = 0.29). B Survival curves representing the new 22G-RNA epimutations duration in each exposure condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). We observed a significant difference between the three conditions (log-rank test, p-value = 8e − 04), but the difference was not dose-dependent. C Boxplot of piRNA epimutation rate for each generation of the MA lines compared to the pre-mutation generation F0 and for each condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). No significant difference was observed between the conditions (Kruskal–Wallis rank-sum test, p-value = 0.90). D Survival curves representing the new piRNA epimutations duration in each exposure condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). We observed a significant difference between the three conditions (log-rank test, p-value = 3.2e − 04) with slightly higher survival changes in epimutation in the control condition. E Boxplot of miRNA epimutations rate for each generation of the MA lines compared to the pre-mutation generation F0 and for each condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). No significant difference was observed between the conditions (Dunn’s Kruskal–Wallis multiple comparison, control vs. LD: p-value = 0.28; control vs. HD: p-value = 0.25). F Survival curves representing the new miRNA epimutations duration in each exposure condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). We observed a significant difference between the three conditions (log-rank test, p-value = 5.5e − 03) with slightly higher survival changes in epimutation in the control condition. G Boxplot of 26G-RNA epimutations rate for each generation of the MA lines compared to the pre-mutation generation F0 and for each condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). No significant difference was observed between the conditions (Kruskal–Wallis rank-sum test, p-value = 0.52). H Survival curves representing the new 26G-RNA epimutations duration in each exposure condition: control (blue), cisplatin low dose (green) and cisplatin high dose (red). We observed a significant difference between the three conditions (log-rank test, p-value = 0.03 with slightly higher survival changes in epimutation in the cisplatin low-dose condition. For A, C, E and G, each dot represents a generation, and data from two lineages per condition were combined giving a number of replicates of N = 19 for control, N = 18 for low dose and N = 19 for high dose. For B, D, F and H, each curve was built using the two lineages per condition as biological replicates (N = 2 for each condition). Supporting data for the whole figure can be found in the Excel file: “Additional file 18”